The big point I make is I'm still here. I'm still me. -- Alan Romatowski
On this day, he's not forgetting words in midsentence. He doesn't feel confused about anything. Alan insightfully answers questions posed by his neurologist, Dr. Oscar Lopez, about what might be happening to the Alzheimer's-related amyloid plaque infiltrating his brain.
To read more about Alan Romatowski -- go here.
Subscribe to The Alzheimer's Reading Room--via Email
Researchers want to see if the drug can slow the progression of Alzheimer’s disease by blocking the amyloid precursor protein, which causes the brain cells to stop working. Amyloid beta peptide is the primary protein found in amyloid plaques in the brains of patients with Alzheimer’s disease. It is expected that by blocking the formation of this peptide, the rate of disease progression can be slowed.
Our goal is to explore if this investigational drug can help control the progression of Alzheimer’s, said Franklin Watkins, M.D., the principal investigator for the study and medical director for the Acute Care for the Elderly Unit at the Medical Center. Most current therapies for Alzheimer’s treat the symptoms associated with it and not the disease itself. It is important for patients and families affected by Alzheimer’s to consider participating in clinical studies. They are the best chance we have for fighting this disease.
This clinical trial has its own website - Investigational Clinical Amyloid Research in Alzheimer's (ICARA).
To view the ICARA study site -- go here.
The ICARA website has a separate page where you can apply and determine if you are eligible to be interviewed for the clinical trial.
- If you want to determine if there is a study location near you -- go here and enter your zip code. There are 193 locations in North American alone so this is a widely available clinical trial.
- If you would like to see if you or a loved one is eligible -- go here and fill out the form on the Internet. This is a first necessary step if you want to participate in the clinical trial.
If you are unable to use the Internet, or if you are seriously interested in the clinical trial my suggestion would be to call this telephone number-- 877-797-8839 -- to start the process.
Go here to see all the on-going Bapineuzumab clinical trials.
Investing Elan Corporation, stock symbol ELN.
Popular articles on the Alzheimer's Reading Room
- Worried About Alzheimer's Disease
- Dementia and the Eight Types of Dementia
- H1N1 Flu Virus Everything You Need to Know
- Does the Combination of Aricept and Namenda Help Slow the Rate of Decline in Alzheimer's Patients
- Test Your Memory (TYM) for Alzheimer's or Dementia in Five Minutes
- Dimebon Connection Study
- The Metamorphosis of This Alzheimer's Caregiver (Part One)
- The Mini-Cog Test for Alzheimer's and Dementia
- Worried about Alzheimer's? Five Ways to Protect Yourself
- Is it Really Alzheimer's or Something Else?
- Alzheimer's Wandering Why it Happens and What to Do
- 50 Good Reasons to Subscribe to the Alzheimer's Reading Room Now
- World Health Care Spending and Performance Ranking by Country (Table)
- Urinary Incontinence -- How We Beat Alzheimer's Incontinence
- Are Alzheimer's Caregivers the Forgotten?
- A Simple Three Minute Test Can Detect the Earliest Stage of Alzheimer's Disease
- Wii a Useful Tool for Alzheimer's Caregivers
- 2009 Alzheimer's Disease Facts and Figures
Bob DeMarco is the editor of the Alzheimer's Reading Room and an Alzheimer's caregiver. The Alzheimer's Reading Room is the number one website on the Internet for news, advice, and insight into Alzheimer's disease. Bob has written more than 950 articles with more than 8,000 links on the Internet. Bob resides in Delray Beach, FL.
Original content Bob DeMarco, Alzheimer's Reading Room
